These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Strengthening the AntiTumor NK Cell Function for the Treatment of Ovarian Cancer. Greppi M; Tabellini G; Patrizi O; Candiani S; Decensi A; Parolini S; Sivori S; Pesce S; Paleari L; Marcenaro E Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30791364 [TBL] [Abstract][Full Text] [Related]
6. Effect of targeted ovarian cancer immunotherapy using ovarian cancer stem cell vaccine. Wu D; Wang J; Cai Y; Ren M; Zhang Y; Shi F; Zhao F; He X; Pan M; Yan C; Dou J J Ovarian Res; 2015 Oct; 8():68. PubMed ID: 26497895 [TBL] [Abstract][Full Text] [Related]
7. The human Müllerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer. Validation using the mAb 12G4. Kersual N; Garambois V; Chardès T; Pouget JP; Salhi I; Bascoul-Mollevi C; Bibeau F; Busson M; Vié H; Clémenceau B; Behrens CK; Estupina P; Pèlegrin A; Navarro-Teulon I MAbs; 2014; 6(5):1314-26. PubMed ID: 25517316 [TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor expression correlates with serum CA125 and represents a useful tool in prediction of refractoriness to platinum-based chemotherapy and ascites formation in epithelial ovarian cancer. Masoumi-Moghaddam S; Amini A; Wei AQ; Robertson G; Morris DL Oncotarget; 2015 Sep; 6(29):28491-501. PubMed ID: 26143638 [TBL] [Abstract][Full Text] [Related]
9. The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (review). Oei AL; Sweep FC; Thomas CM; Boerman OC; Massuger LF Int J Oncol; 2008 Jun; 32(6):1145-57. PubMed ID: 18497976 [TBL] [Abstract][Full Text] [Related]
10. Tumor-infiltrating T cells in epithelial ovarian cancer: predictors of prognosis and biological basis of immunotherapy. Wang W; Zou W; Liu JR Gynecol Oncol; 2018 Oct; 151(1):1-3. PubMed ID: 30243508 [No Abstract] [Full Text] [Related]
15. Ovarian cancer and the immune system - The role of targeted therapies. Turner TB; Buchsbaum DJ; Straughn JM; Randall TD; Arend RC Gynecol Oncol; 2016 Aug; 142(2):349-56. PubMed ID: 27174875 [TBL] [Abstract][Full Text] [Related]
16. Targeting cytokines secreted by CD4 Ke X; Shen L Scand J Immunol; 2019 Feb; 89(2):e12736. PubMed ID: 30485902 [TBL] [Abstract][Full Text] [Related]
17. Natural Killer Cells Response to IL-2 Stimulation Is Distinct between Ascites with the Presence or Absence of Malignant Cells in Ovarian Cancer Patients. da Silva RF; Yoshida A; Cardozo DM; Jales RM; Paust S; Derchain S; Guimarães F Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28513532 [TBL] [Abstract][Full Text] [Related]
18. Immune response evaluation through determination of type 1, type 2, and type 17 patterns in patients with epithelial ovarian cancer. Cândido EB; Silva LM; Carvalho AT; Lamaita RM; Filho RM; Cota BD; da Silva-Filho AL Reprod Sci; 2013 Jul; 20(7):828-37. PubMed ID: 23239818 [TBL] [Abstract][Full Text] [Related]
19. Clinical management of epithelial ovarian cancer during pregnancy. Grimm D; Woelber L; Trillsch F; Keller-v Amsberg G; Mahner S Eur J Cancer; 2014 Mar; 50(5):963-71. PubMed ID: 24462638 [TBL] [Abstract][Full Text] [Related]